Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosaprepitant Dimeglumine

FDA-approved product (powder, intravenous), marketed as Emend, Focinvez, Fosaprepitant Dimeglumine and 1 more.

Registered studies
21
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Fosaprepitant Dimeglumine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fosaprepitant Dimeglumine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosaprepitant Dimeglumine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

    NCT00818259 · start 2009-02-05

    Registered record
    Registry ID
    NCT00818259
    Conditions
    Chemotherapy-Induced Nausea and Vomiting
    Interventions
    Experimental: aprepitant; Experimental: fosaprepitant; Comparator: ondansetron; Ondansetron; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-02-05
    Completion
    2014-01-20
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting
    InterventionExperimental: aprepitant; Experimental: fosaprepitant; Comparator: ondansetron; Ondansetron +1 more
    PhasePhase 1
    Registry statusTerminated

  • Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

    NCT00895245 · start 2009-02

    Registered record
    Registry ID
    NCT00895245
    Conditions
    Nausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx
    Interventions
    fosaprepitant dimeglumine; cisplatin; palonosetron hydrochloride; dexamethasone; Functional Living Index-Emesis Questionnaire; Emesis Diary; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2011-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity +7 more
    Interventionfosaprepitant dimeglumine; cisplatin; palonosetron hydrochloride; dexamethasone +3 more
    PhasePhase 2
    Registry statusTerminated

  • A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

    NCT00945321 · start 2009-02

    Registered record
    Registry ID
    NCT00945321
    Conditions
    Chemotherapy-Induced Nausea and Vomiting
    Interventions
    aprepitant 165 mg; Comparator: aprepitant 185 mg; Comparator: fosaprepitant 150 mg; Comparator: aprepitant with food
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2009-03
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting
    Interventionaprepitant 165 mg; Comparator: aprepitant 185 mg; Comparator: fosaprepitant 150 mg; Comparator: aprepitant with food
    PhasePhase 1
    Registry statusCompleted

  • Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

    NCT01031953 · start 2008-08

    Registered record
    Registry ID
    NCT01031953
    Conditions
    Breakthrough Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    fosaprepitant dimeglumine; systemic chemotherapy; survey administration; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2013-02
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreakthrough Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
    Interventionfosaprepitant dimeglumine; systemic chemotherapy; survey administration; quality-of-life assessment
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

    NCT00619359 · start 2008-02

    Registered record
    Registry ID
    NCT00619359
    Conditions
    Chemotherapy-Induced Nausea and Vomiting (CINV)
    Interventions
    Comparator: fosaprepitant dimeglumine; Comparator: Aprepitant; Dexamethasone; Dexamethasone; Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-06
    Enrolment
    2,322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting (CINV)
    InterventionComparator: fosaprepitant dimeglumine; Comparator: Aprepitant; Dexamethasone; Dexamethasone +1 more
    PhasePhase 3
    Registry statusCompleted

  • Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

    NCT00337727 · start 2007-01-01

    Registered record
    Registry ID
    NCT00337727
    Conditions
    Chemotherapy-Induced Nausea and Vomiting
    Interventions
    aprepitant; Comparator: ondansetron; Comparator: dexamethasone; Comparator: fosaprepitant dimeglumine; Comparator; Placebo (unspecified); Comparator; Placebo (unspecified)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-01-01
    Completion
    2008-11-19
    Enrolment
    848

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting
    Interventionaprepitant; Comparator: ondansetron; Comparator: dexamethasone; Comparator: fosaprepitant dimeglumine +4 more
    PhasePhase 3
    Registry statusCompleted